| Ytd | -60.12% | |
| 1y | -91.49% |
| Open | 5.79 | Prev Close | 5.90 | Low | 5.79 | High | 5.79 | Mkt Cap | 4.25M |
| Vol | 2.27K | Avg Vol | 15.48K | EPS | -48.10 | P/E | -0.12 | Forward P/E | -0.98 |
| Beta | 0.22 | Short Ratio | 1.62 | Inst. Own | 36.40% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-11 | 50-d Avg | 8.41 | 200-d Avg | 20.29 | 1yr Est | 2.50 |
XAIR News
Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 40.9% to $0.16 during Thursday's pre-
Beyond Air, Inc. (XAIR) Q4 2026 Earnings Call Transcript
U.S. stock futures slipped on Friday after a mixed close on Thursday.
On Friday, Beyond Air (NASDAQ:XAIR) discussed fourth-quarter financial results during its earnings c
Companies Reporting Before The Bell • Beyond Air (NASDAQ:XAIR) is estimated to report quarterly loss
Beyond Air (NASDAQ:XAIR) reported quarterly losses of $(0.77) per share which missed the analyst con
Revenue increased by 107% year-over-year to $7.7 million in the full fiscal year 2026; increased rev
The CNN Fear & Greed Index, measuring market sentiment, showed a slight decline on Thursday, rem
U.S. stock futures are down, but some stocks to watch today include Apogee, BitGo, Cineverse, Synapt
GARDEN CITY, N.Y., June 22, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” o
Special Meeting of Stockholders Scheduled for June 18, 2026 at 4:30 p. m. Eastern Time Proxies have
Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focu
GARDEN CITY, N.Y., June 01, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-s
The Phase 1 trial (NCT05351502) was a clinical proof-of-concept trial that assessed the intratumoral
Updated AACR poster data show continued survival follow-up in heavily pre ‑ treated patients followi
https://x.com/PatentGrants/status/2045229993731776669
GARDEN CITY, N.Y., April 15, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial-
Beyond Air, Inc. (NASDAQ:XAIR), a commercial-stage medical device and biopharmaceutical company focu
Beyond Air, Inc. (NASDAQ: XAIR - Get Free Report) was the target of a large drop in short interest i
Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage
Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitr
Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is schedule
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” o
Beyond Air, Inc. (XAIR) Q3 2026 Earnings Call Transcript
Increased revenue by 105% year-over-year (YoY) to $2.2 million in fiscal Q3 Maintain fiscal year 202
GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” o
Beyond Air, Inc. (NASDAQ: XAIR - Get Free Report) was the target of a large decrease in short intere
Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global
Beyond Air, Inc. (NASDAQ: XAIR - Get Free Report) saw a significant decline in short interest in Dec
Beyond Air (NASDAQ: XAIR - Get Free Report) and Cartesian Therapeutics (NASDAQ: RNAC - Get Free Repo
US stock futures higher. Chagee Holdings, Tilray Brands, Globus Maritime, Post Holdings, and Beyond
GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” o
